nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—ABCB1—hematologic cancer	0.0726	1	CbGaD
Dapagliflozin—CYP2A6—Methoxsalen—hematologic cancer	0.0237	0.0395	CbGbCtD
Dapagliflozin—UGT1A9—Irinotecan—hematologic cancer	0.0212	0.0354	CbGbCtD
Dapagliflozin—UGT2B7—Epirubicin—hematologic cancer	0.0206	0.0344	CbGbCtD
Dapagliflozin—CYP1A2—Anagrelide—hematologic cancer	0.0202	0.0338	CbGbCtD
Dapagliflozin—CYP1A1—Methoxsalen—hematologic cancer	0.0202	0.0338	CbGbCtD
Dapagliflozin—CYP1A1—Bortezomib—hematologic cancer	0.0192	0.0321	CbGbCtD
Dapagliflozin—CYP1A1—Daunorubicin—hematologic cancer	0.0184	0.0307	CbGbCtD
Dapagliflozin—CYP2A6—Ifosfamide—hematologic cancer	0.0173	0.0288	CbGbCtD
Dapagliflozin—CYP1A1—Thalidomide—hematologic cancer	0.0168	0.028	CbGbCtD
Dapagliflozin—CYP1A1—Dacarbazine—hematologic cancer	0.0144	0.0241	CbGbCtD
Dapagliflozin—CYP2C9—Bexarotene—hematologic cancer	0.0126	0.0211	CbGbCtD
Dapagliflozin—ABCB1—Lenalidomide—hematologic cancer	0.0123	0.0205	CbGbCtD
Dapagliflozin—CYP2A6—Prednisolone—hematologic cancer	0.0115	0.0192	CbGbCtD
Dapagliflozin—CYP1A1—Dasatinib—hematologic cancer	0.0113	0.0189	CbGbCtD
Dapagliflozin—CYP2D6—Lomustine—hematologic cancer	0.0107	0.0179	CbGbCtD
Dapagliflozin—CYP1A2—Carmustine—hematologic cancer	0.0106	0.0177	CbGbCtD
Dapagliflozin—CYP2C9—Idarubicin—hematologic cancer	0.0105	0.0175	CbGbCtD
Dapagliflozin—CYP2D6—Idarubicin—hematologic cancer	0.00957	0.016	CbGbCtD
Dapagliflozin—CYP1A2—Methoxsalen—hematologic cancer	0.00903	0.0151	CbGbCtD
Dapagliflozin—CYP1A2—Bortezomib—hematologic cancer	0.00859	0.0143	CbGbCtD
Dapagliflozin—CYP1A2—Daunorubicin—hematologic cancer	0.00822	0.0137	CbGbCtD
Dapagliflozin—CYP2D6—Hydroxyurea—hematologic cancer	0.00814	0.0136	CbGbCtD
Dapagliflozin—CYP1A2—Alitretinoin—hematologic cancer	0.00805	0.0134	CbGbCtD
Dapagliflozin—CYP2C9—Bortezomib—hematologic cancer	0.00774	0.0129	CbGbCtD
Dapagliflozin—CYP1A2—Thalidomide—hematologic cancer	0.00749	0.0125	CbGbCtD
Dapagliflozin—CYP3A4—Bexarotene—hematologic cancer	0.00735	0.0123	CbGbCtD
Dapagliflozin—ABCB1—Daunorubicin—hematologic cancer	0.00719	0.012	CbGbCtD
Dapagliflozin—CYP2D6—Bortezomib—hematologic cancer	0.00708	0.0118	CbGbCtD
Dapagliflozin—ABCB1—Alitretinoin—hematologic cancer	0.00704	0.0118	CbGbCtD
Dapagliflozin—CYP3A4—Lomustine—hematologic cancer	0.00683	0.0114	CbGbCtD
Dapagliflozin—CYP3A4—Busulfan—hematologic cancer	0.00683	0.0114	CbGbCtD
Dapagliflozin—CYP2A6—Dexamethasone—hematologic cancer	0.00679	0.0113	CbGbCtD
Dapagliflozin—CYP2C9—Thalidomide—hematologic cancer	0.00675	0.0113	CbGbCtD
Dapagliflozin—CYP1A2—Dacarbazine—hematologic cancer	0.00644	0.0107	CbGbCtD
Dapagliflozin—CYP2C9—Teniposide—hematologic cancer	0.00643	0.0107	CbGbCtD
Dapagliflozin—CYP1A2—Imatinib—hematologic cancer	0.0063	0.0105	CbGbCtD
Dapagliflozin—CYP3A4—Thiotepa—hematologic cancer	0.00609	0.0102	CbGbCtD
Dapagliflozin—CYP2C9—Ifosfamide—hematologic cancer	0.00594	0.00992	CbGbCtD
Dapagliflozin—CYP1A1—Dexamethasone—hematologic cancer	0.0058	0.00968	CbGbCtD
Dapagliflozin—CYP2C9—Imatinib—hematologic cancer	0.00567	0.00947	CbGbCtD
Dapagliflozin—ABCB1—Imatinib—hematologic cancer	0.00551	0.00919	CbGbCtD
Dapagliflozin—CYP2D6—Imatinib—hematologic cancer	0.00519	0.00866	CbGbCtD
Dapagliflozin—CYP2C9—Nilotinib—hematologic cancer	0.00516	0.00861	CbGbCtD
Dapagliflozin—CYP1A2—Dasatinib—hematologic cancer	0.00506	0.00844	CbGbCtD
Dapagliflozin—ABCB1—Nilotinib—hematologic cancer	0.005	0.00835	CbGbCtD
Dapagliflozin—ABCB1—Vinorelbine—hematologic cancer	0.00496	0.00828	CbGbCtD
Dapagliflozin—CYP3A4—Methoxsalen—hematologic cancer	0.00473	0.0079	CbGbCtD
Dapagliflozin—CYP2D6—Nilotinib—hematologic cancer	0.00471	0.00787	CbGbCtD
Dapagliflozin—CYP2D6—Vinorelbine—hematologic cancer	0.00467	0.00781	CbGbCtD
Dapagliflozin—CYP3A4—Bortezomib—hematologic cancer	0.0045	0.00752	CbGbCtD
Dapagliflozin—ABCB1—Dasatinib—hematologic cancer	0.00442	0.00738	CbGbCtD
Dapagliflozin—ABCB1—Mitoxantrone—hematologic cancer	0.00437	0.00729	CbGbCtD
Dapagliflozin—CYP3A4—Daunorubicin—hematologic cancer	0.00431	0.00719	CbGbCtD
Dapagliflozin—ABCB1—Betamethasone—hematologic cancer	0.00389	0.0065	CbGbCtD
Dapagliflozin—ABCB1—Gemcitabine—hematologic cancer	0.00386	0.00644	CbGbCtD
Dapagliflozin—ABCB1—Prednisolone—hematologic cancer	0.00384	0.00641	CbGbCtD
Dapagliflozin—CYP3A4—Cytarabine—hematologic cancer	0.0038	0.00634	CbGbCtD
Dapagliflozin—CYP3A4—Teniposide—hematologic cancer	0.00374	0.00625	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—hematologic cancer	0.00363	0.00606	CbGbCtD
Dapagliflozin—CYP3A4—Ifosfamide—hematologic cancer	0.00345	0.00577	CbGbCtD
Dapagliflozin—ABCB1—Irinotecan—hematologic cancer	0.00344	0.00574	CbGbCtD
Dapagliflozin—CYP3A4—Imatinib—hematologic cancer	0.0033	0.00551	CbGbCtD
Dapagliflozin—SLC5A11—blood—hematologic cancer	0.00328	0.15	CbGeAlD
Dapagliflozin—CYP1A2—Etoposide—hematologic cancer	0.00315	0.00526	CbGbCtD
Dapagliflozin—CYP3A4—Ruxolitinib—hematologic cancer	0.00311	0.00519	CbGbCtD
Dapagliflozin—ABCB1—Vinblastine—hematologic cancer	0.00306	0.0051	CbGbCtD
Dapagliflozin—ABCB1—Vincristine—hematologic cancer	0.00301	0.00502	CbGbCtD
Dapagliflozin—CYP3A4—Nilotinib—hematologic cancer	0.003	0.00501	CbGbCtD
Dapagliflozin—CYP3A4—Vinorelbine—hematologic cancer	0.00297	0.00496	CbGbCtD
Dapagliflozin—CYP2C9—Cisplatin—hematologic cancer	0.00289	0.00482	CbGbCtD
Dapagliflozin—CYP2D6—Vinblastine—hematologic cancer	0.00288	0.00481	CbGbCtD
Dapagliflozin—ABCB1—Cisplatin—hematologic cancer	0.0028	0.00468	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—hematologic cancer	0.00275	0.0046	CbGbCtD
Dapagliflozin—SLC5A2—blood—hematologic cancer	0.00273	0.125	CbGeAlD
Dapagliflozin—CYP3A4—Triamcinolone—hematologic cancer	0.00272	0.00454	CbGbCtD
Dapagliflozin—CYP3A4—Dasatinib—hematologic cancer	0.00265	0.00442	CbGbCtD
Dapagliflozin—CYP3A4—Mitoxantrone—hematologic cancer	0.00262	0.00437	CbGbCtD
Dapagliflozin—CYP2C9—Dexamethasone—hematologic cancer	0.00233	0.0039	CbGbCtD
Dapagliflozin—CYP3A4—Betamethasone—hematologic cancer	0.00233	0.00389	CbGbCtD
Dapagliflozin—CYP3A4—Prednisolone—hematologic cancer	0.0023	0.00384	CbGbCtD
Dapagliflozin—ABCB1—Dexamethasone—hematologic cancer	0.00226	0.00378	CbGbCtD
Dapagliflozin—SLC5A2—testis—hematologic cancer	0.00226	0.103	CbGeAlD
Dapagliflozin—CYP3A4—Prednisone—hematologic cancer	0.00217	0.00363	CbGbCtD
Dapagliflozin—CYP2D6—Dexamethasone—hematologic cancer	0.00213	0.00356	CbGbCtD
Dapagliflozin—CYP3A4—Irinotecan—hematologic cancer	0.00206	0.00344	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—hematologic cancer	0.00188	0.00314	CbGbCtD
Dapagliflozin—CYP3A4—Vinblastine—hematologic cancer	0.00183	0.00306	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—hematologic cancer	0.00182	0.00304	CbGbCtD
Dapagliflozin—SLC5A1—lung—hematologic cancer	0.00182	0.0829	CbGeAlD
Dapagliflozin—CYP3A4—Vincristine—hematologic cancer	0.0018	0.00301	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—hematologic cancer	0.00177	0.00296	CbGbCtD
Dapagliflozin—SLC5A1—testis—hematologic cancer	0.00171	0.0782	CbGeAlD
Dapagliflozin—UGT2B4—lung—hematologic cancer	0.00167	0.0764	CbGeAlD
Dapagliflozin—CYP3A4—Etoposide—hematologic cancer	0.00165	0.00276	CbGbCtD
Dapagliflozin—CYP3A4—Dexamethasone—hematologic cancer	0.00136	0.00227	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—hematologic cancer	0.00113	0.00188	CbGbCtD
Dapagliflozin—UGT2B7—testis—hematologic cancer	0.000869	0.0397	CbGeAlD
Dapagliflozin—Canagliflozin—ALB—hematologic cancer	0.00082	0.512	CrCbGaD
Dapagliflozin—Canagliflozin—ABCB1—hematologic cancer	0.000782	0.488	CrCbGaD
Dapagliflozin—CYP2A6—lung—hematologic cancer	0.00066	0.0301	CbGeAlD
Dapagliflozin—CYP1A2—hematopoietic system—hematologic cancer	0.000597	0.0273	CbGeAlD
Dapagliflozin—CYP1A1—hematopoietic system—hematologic cancer	0.000589	0.0269	CbGeAlD
Dapagliflozin—CYP2C9—hematopoietic system—hematologic cancer	0.000567	0.0259	CbGeAlD
Dapagliflozin—CYP3A4—hematopoietic system—hematologic cancer	0.000432	0.0197	CbGeAlD
Dapagliflozin—CYP2D6—hematopoietic system—hematologic cancer	0.000425	0.0194	CbGeAlD
Dapagliflozin—CYP1A2—blood—hematologic cancer	0.000396	0.0181	CbGeAlD
Dapagliflozin—CYP1A1—blood—hematologic cancer	0.00039	0.0178	CbGeAlD
Dapagliflozin—CYP2C9—blood—hematologic cancer	0.000376	0.0171	CbGeAlD
Dapagliflozin—CYP1A2—lung—hematologic cancer	0.000347	0.0158	CbGeAlD
Dapagliflozin—CYP1A1—lung—hematologic cancer	0.000342	0.0156	CbGeAlD
Dapagliflozin—ABCB1—hematopoietic system—hematologic cancer	0.000306	0.014	CbGeAlD
Dapagliflozin—CYP3A4—blood—hematologic cancer	0.000286	0.0131	CbGeAlD
Dapagliflozin—CYP2D6—blood—hematologic cancer	0.000282	0.0129	CbGeAlD
Dapagliflozin—CYP1A1—lymph node—hematologic cancer	0.000234	0.0107	CbGeAlD
Dapagliflozin—CYP2D6—testis—hematologic cancer	0.000233	0.0106	CbGeAlD
Dapagliflozin—ABCB1—gonad—hematologic cancer	0.000233	0.0106	CbGeAlD
Dapagliflozin—ABCB1—blood—hematologic cancer	0.000203	0.00926	CbGeAlD
Dapagliflozin—ABCB1—bone marrow—hematologic cancer	0.000196	0.00896	CbGeAlD
Dapagliflozin—ABCB1—lung—hematologic cancer	0.000178	0.00811	CbGeAlD
Dapagliflozin—ABCB1—testis—hematologic cancer	0.000168	0.00766	CbGeAlD
Dapagliflozin—ABCB1—lymph node—hematologic cancer	0.000122	0.00555	CbGeAlD
Dapagliflozin—Influenza—Epirubicin—hematologic cancer	5.78e-05	0.000305	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—hematologic cancer	5.78e-05	0.000304	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—hematologic cancer	5.76e-05	0.000303	CcSEcCtD
Dapagliflozin—Body temperature increased—Vincristine—hematologic cancer	5.73e-05	0.000302	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—hematologic cancer	5.7e-05	0.0003	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—hematologic cancer	5.67e-05	0.000299	CcSEcCtD
Dapagliflozin—Dizziness—Vinorelbine—hematologic cancer	5.66e-05	0.000298	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—hematologic cancer	5.65e-05	0.000298	CcSEcCtD
Dapagliflozin—Nausea—Lenalidomide—hematologic cancer	5.65e-05	0.000298	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—hematologic cancer	5.63e-05	0.000297	CcSEcCtD
Dapagliflozin—Hypertension—Triamcinolone—hematologic cancer	5.63e-05	0.000297	CcSEcCtD
Dapagliflozin—Urticaria—Mitoxantrone—hematologic cancer	5.6e-05	0.000295	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisolone—hematologic cancer	5.59e-05	0.000295	CcSEcCtD
Dapagliflozin—Hypersensitivity—Carmustine—hematologic cancer	5.59e-05	0.000294	CcSEcCtD
Dapagliflozin—Body temperature increased—Mitoxantrone—hematologic cancer	5.58e-05	0.000294	CcSEcCtD
Dapagliflozin—Body temperature increased—Irinotecan—hematologic cancer	5.58e-05	0.000294	CcSEcCtD
Dapagliflozin—Nausea—Hydroxyurea—hematologic cancer	5.57e-05	0.000294	CcSEcCtD
Dapagliflozin—Hypersensitivity—Alitretinoin—hematologic cancer	5.54e-05	0.000292	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—hematologic cancer	5.54e-05	0.000292	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cisplatin—hematologic cancer	5.53e-05	0.000291	CcSEcCtD
Dapagliflozin—Rash—Bortezomib—hematologic cancer	5.52e-05	0.000291	CcSEcCtD
Dapagliflozin—Dermatitis—Bortezomib—hematologic cancer	5.52e-05	0.000291	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—hematologic cancer	5.51e-05	0.00029	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—hematologic cancer	5.51e-05	0.00029	CcSEcCtD
Dapagliflozin—Headache—Bortezomib—hematologic cancer	5.49e-05	0.000289	CcSEcCtD
Dapagliflozin—Discomfort—Triamcinolone—hematologic cancer	5.48e-05	0.000289	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—hematologic cancer	5.48e-05	0.000289	CcSEcCtD
Dapagliflozin—Rash—Bleomycin—hematologic cancer	5.48e-05	0.000289	CcSEcCtD
Dapagliflozin—Dermatitis—Bleomycin—hematologic cancer	5.47e-05	0.000288	CcSEcCtD
Dapagliflozin—Hypersensitivity—Ifosfamide—hematologic cancer	5.47e-05	0.000288	CcSEcCtD
Dapagliflozin—Body temperature increased—Gemcitabine—hematologic cancer	5.43e-05	0.000286	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—hematologic cancer	5.42e-05	0.000285	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—hematologic cancer	5.41e-05	0.000285	CcSEcCtD
Dapagliflozin—Angioedema—Dexamethasone—hematologic cancer	5.41e-05	0.000285	CcSEcCtD
Dapagliflozin—Angioedema—Betamethasone—hematologic cancer	5.41e-05	0.000285	CcSEcCtD
Dapagliflozin—Dizziness—Thiotepa—hematologic cancer	5.4e-05	0.000284	CcSEcCtD
Dapagliflozin—Rash—Vinorelbine—hematologic cancer	5.39e-05	0.000284	CcSEcCtD
Dapagliflozin—Dermatitis—Vinorelbine—hematologic cancer	5.39e-05	0.000284	CcSEcCtD
Dapagliflozin—Headache—Vinorelbine—hematologic cancer	5.36e-05	0.000282	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—hematologic cancer	5.35e-05	0.000282	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—hematologic cancer	5.34e-05	0.000281	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vincristine—hematologic cancer	5.34e-05	0.000281	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Triamcinolone—hematologic cancer	5.32e-05	0.00028	CcSEcCtD
Dapagliflozin—Oedema—Triamcinolone—hematologic cancer	5.32e-05	0.00028	CcSEcCtD
Dapagliflozin—Infection—Triamcinolone—hematologic cancer	5.29e-05	0.000278	CcSEcCtD
Dapagliflozin—Dizziness—Thalidomide—hematologic cancer	5.22e-05	0.000275	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—hematologic cancer	5.21e-05	0.000275	CcSEcCtD
Dapagliflozin—Nausea—Bortezomib—hematologic cancer	5.2e-05	0.000274	CcSEcCtD
Dapagliflozin—Hypersensitivity—Irinotecan—hematologic cancer	5.2e-05	0.000274	CcSEcCtD
Dapagliflozin—Hypersensitivity—Mitoxantrone—hematologic cancer	5.2e-05	0.000274	CcSEcCtD
Dapagliflozin—Nausea—Bleomycin—hematologic cancer	5.16e-05	0.000272	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—hematologic cancer	5.16e-05	0.000272	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—hematologic cancer	5.16e-05	0.000272	CcSEcCtD
Dapagliflozin—Malnutrition—Prednisone—hematologic cancer	5.15e-05	0.000271	CcSEcCtD
Dapagliflozin—Rash—Thiotepa—hematologic cancer	5.15e-05	0.000271	CcSEcCtD
Dapagliflozin—Dermatitis—Thiotepa—hematologic cancer	5.14e-05	0.000271	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Triamcinolone—hematologic cancer	5.14e-05	0.000271	CcSEcCtD
Dapagliflozin—Headache—Thiotepa—hematologic cancer	5.12e-05	0.000269	CcSEcCtD
Dapagliflozin—Hypertension—Dexamethasone—hematologic cancer	5.11e-05	0.000269	CcSEcCtD
Dapagliflozin—Hypertension—Betamethasone—hematologic cancer	5.11e-05	0.000269	CcSEcCtD
Dapagliflozin—Nausea—Vinorelbine—hematologic cancer	5.08e-05	0.000268	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—hematologic cancer	5.07e-05	0.000267	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—hematologic cancer	5.06e-05	0.000267	CcSEcCtD
Dapagliflozin—Body temperature increased—Cisplatin—hematologic cancer	5.06e-05	0.000267	CcSEcCtD
Dapagliflozin—Dizziness—Carmustine—hematologic cancer	5.02e-05	0.000264	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—hematologic cancer	5.02e-05	0.000264	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—hematologic cancer	5.01e-05	0.000264	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—hematologic cancer	5e-05	0.000264	CcSEcCtD
Dapagliflozin—Rash—Thalidomide—hematologic cancer	4.98e-05	0.000262	CcSEcCtD
Dapagliflozin—Discomfort—Betamethasone—hematologic cancer	4.98e-05	0.000262	CcSEcCtD
Dapagliflozin—Discomfort—Dexamethasone—hematologic cancer	4.98e-05	0.000262	CcSEcCtD
Dapagliflozin—Dermatitis—Thalidomide—hematologic cancer	4.98e-05	0.000262	CcSEcCtD
Dapagliflozin—Dizziness—Alitretinoin—hematologic cancer	4.97e-05	0.000262	CcSEcCtD
Dapagliflozin—Headache—Thalidomide—hematologic cancer	4.95e-05	0.000261	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—hematologic cancer	4.94e-05	0.00026	CcSEcCtD
Dapagliflozin—Dizziness—Ifosfamide—hematologic cancer	4.91e-05	0.000259	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—hematologic cancer	4.88e-05	0.000257	CcSEcCtD
Dapagliflozin—Nausea—Thiotepa—hematologic cancer	4.85e-05	0.000256	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—hematologic cancer	4.85e-05	0.000255	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Betamethasone—hematologic cancer	4.83e-05	0.000254	CcSEcCtD
Dapagliflozin—Oedema—Dexamethasone—hematologic cancer	4.83e-05	0.000254	CcSEcCtD
Dapagliflozin—Oedema—Betamethasone—hematologic cancer	4.83e-05	0.000254	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Dexamethasone—hematologic cancer	4.83e-05	0.000254	CcSEcCtD
Dapagliflozin—Infection—Dexamethasone—hematologic cancer	4.8e-05	0.000253	CcSEcCtD
Dapagliflozin—Infection—Betamethasone—hematologic cancer	4.8e-05	0.000253	CcSEcCtD
Dapagliflozin—Dizziness—Vincristine—hematologic cancer	4.79e-05	0.000252	CcSEcCtD
Dapagliflozin—Rash—Carmustine—hematologic cancer	4.78e-05	0.000252	CcSEcCtD
Dapagliflozin—Dermatitis—Carmustine—hematologic cancer	4.78e-05	0.000252	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—hematologic cancer	4.77e-05	0.000251	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—hematologic cancer	4.77e-05	0.000251	CcSEcCtD
Dapagliflozin—Headache—Carmustine—hematologic cancer	4.75e-05	0.00025	CcSEcCtD
Dapagliflozin—Rash—Alitretinoin—hematologic cancer	4.74e-05	0.00025	CcSEcCtD
Dapagliflozin—Dermatitis—Alitretinoin—hematologic cancer	4.73e-05	0.000249	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cisplatin—hematologic cancer	4.72e-05	0.000249	CcSEcCtD
Dapagliflozin—Headache—Alitretinoin—hematologic cancer	4.71e-05	0.000248	CcSEcCtD
Dapagliflozin—Angioedema—Prednisone—hematologic cancer	4.71e-05	0.000248	CcSEcCtD
Dapagliflozin—Nausea—Thalidomide—hematologic cancer	4.69e-05	0.000247	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—hematologic cancer	4.69e-05	0.000247	CcSEcCtD
Dapagliflozin—Rash—Ifosfamide—hematologic cancer	4.68e-05	0.000247	CcSEcCtD
Dapagliflozin—Dermatitis—Ifosfamide—hematologic cancer	4.68e-05	0.000246	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Dexamethasone—hematologic cancer	4.67e-05	0.000246	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Betamethasone—hematologic cancer	4.67e-05	0.000246	CcSEcCtD
Dapagliflozin—Dizziness—Irinotecan—hematologic cancer	4.66e-05	0.000246	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—hematologic cancer	4.66e-05	0.000245	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—hematologic cancer	4.64e-05	0.000244	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—hematologic cancer	4.64e-05	0.000244	CcSEcCtD
Dapagliflozin—Urticaria—Prednisolone—hematologic cancer	4.6e-05	0.000242	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—hematologic cancer	4.57e-05	0.000241	CcSEcCtD
Dapagliflozin—Rash—Vincristine—hematologic cancer	4.57e-05	0.000241	CcSEcCtD
Dapagliflozin—Dermatitis—Vincristine—hematologic cancer	4.56e-05	0.00024	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—hematologic cancer	4.55e-05	0.00024	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—hematologic cancer	4.54e-05	0.000239	CcSEcCtD
Dapagliflozin—Headache—Vincristine—hematologic cancer	4.54e-05	0.000239	CcSEcCtD
Dapagliflozin—Hypotension—Dexamethasone—hematologic cancer	4.51e-05	0.000238	CcSEcCtD
Dapagliflozin—Hypotension—Betamethasone—hematologic cancer	4.51e-05	0.000238	CcSEcCtD
Dapagliflozin—Nausea—Carmustine—hematologic cancer	4.51e-05	0.000237	CcSEcCtD
Dapagliflozin—Nausea—Alitretinoin—hematologic cancer	4.46e-05	0.000235	CcSEcCtD
Dapagliflozin—Hypertension—Prednisone—hematologic cancer	4.45e-05	0.000234	CcSEcCtD
Dapagliflozin—Rash—Irinotecan—hematologic cancer	4.45e-05	0.000234	CcSEcCtD
Dapagliflozin—Rash—Mitoxantrone—hematologic cancer	4.45e-05	0.000234	CcSEcCtD
Dapagliflozin—Dermatitis—Irinotecan—hematologic cancer	4.44e-05	0.000234	CcSEcCtD
Dapagliflozin—Dermatitis—Mitoxantrone—hematologic cancer	4.44e-05	0.000234	CcSEcCtD
Dapagliflozin—Headache—Irinotecan—hematologic cancer	4.42e-05	0.000233	CcSEcCtD
Dapagliflozin—Headache—Mitoxantrone—hematologic cancer	4.42e-05	0.000233	CcSEcCtD
Dapagliflozin—Nausea—Ifosfamide—hematologic cancer	4.41e-05	0.000232	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.36e-05	0.000229	CcSEcCtD
Dapagliflozin—Discomfort—Prednisone—hematologic cancer	4.33e-05	0.000228	CcSEcCtD
Dapagliflozin—Rash—Gemcitabine—hematologic cancer	4.33e-05	0.000228	CcSEcCtD
Dapagliflozin—Dermatitis—Gemcitabine—hematologic cancer	4.33e-05	0.000228	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—hematologic cancer	4.32e-05	0.000228	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—hematologic cancer	4.31e-05	0.000227	CcSEcCtD
Dapagliflozin—Headache—Gemcitabine—hematologic cancer	4.3e-05	0.000227	CcSEcCtD
Dapagliflozin—Nausea—Vincristine—hematologic cancer	4.3e-05	0.000227	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisolone—hematologic cancer	4.26e-05	0.000225	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—hematologic cancer	4.23e-05	0.000223	CcSEcCtD
Dapagliflozin—Urticaria—Triamcinolone—hematologic cancer	4.23e-05	0.000223	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—hematologic cancer	4.21e-05	0.000222	CcSEcCtD
Dapagliflozin—Body temperature increased—Triamcinolone—hematologic cancer	4.21e-05	0.000222	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—hematologic cancer	4.2e-05	0.000221	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—hematologic cancer	4.2e-05	0.000221	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—hematologic cancer	4.2e-05	0.000221	CcSEcCtD
Dapagliflozin—Nausea—Irinotecan—hematologic cancer	4.19e-05	0.000221	CcSEcCtD
Dapagliflozin—Nausea—Mitoxantrone—hematologic cancer	4.19e-05	0.000221	CcSEcCtD
Dapagliflozin—Infection—Prednisone—hematologic cancer	4.18e-05	0.00022	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.17e-05	0.00022	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.17e-05	0.00022	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—hematologic cancer	4.16e-05	0.000219	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—hematologic cancer	4.08e-05	0.000215	CcSEcCtD
Dapagliflozin—Nausea—Gemcitabine—hematologic cancer	4.08e-05	0.000215	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—hematologic cancer	4.06e-05	0.000214	CcSEcCtD
Dapagliflozin—Rash—Cisplatin—hematologic cancer	4.04e-05	0.000213	CcSEcCtD
Dapagliflozin—Dermatitis—Cisplatin—hematologic cancer	4.03e-05	0.000212	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—hematologic cancer	4.03e-05	0.000212	CcSEcCtD
Dapagliflozin—Hypersensitivity—Triamcinolone—hematologic cancer	3.92e-05	0.000207	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—hematologic cancer	3.9e-05	0.000205	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—hematologic cancer	3.88e-05	0.000204	CcSEcCtD
Dapagliflozin—Urticaria—Dexamethasone—hematologic cancer	3.84e-05	0.000202	CcSEcCtD
Dapagliflozin—Urticaria—Betamethasone—hematologic cancer	3.84e-05	0.000202	CcSEcCtD
Dapagliflozin—Dizziness—Prednisolone—hematologic cancer	3.83e-05	0.000202	CcSEcCtD
Dapagliflozin—Body temperature increased—Dexamethasone—hematologic cancer	3.82e-05	0.000201	CcSEcCtD
Dapagliflozin—Body temperature increased—Betamethasone—hematologic cancer	3.82e-05	0.000201	CcSEcCtD
Dapagliflozin—Nausea—Cisplatin—hematologic cancer	3.8e-05	0.0002	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—hematologic cancer	3.73e-05	0.000196	CcSEcCtD
Dapagliflozin—Rash—Etoposide—hematologic cancer	3.7e-05	0.000195	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—hematologic cancer	3.7e-05	0.000195	CcSEcCtD
Dapagliflozin—Headache—Etoposide—hematologic cancer	3.68e-05	0.000194	CcSEcCtD
Dapagliflozin—Rash—Prednisolone—hematologic cancer	3.65e-05	0.000192	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisolone—hematologic cancer	3.64e-05	0.000192	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.64e-05	0.000192	CcSEcCtD
Dapagliflozin—Headache—Prednisolone—hematologic cancer	3.62e-05	0.000191	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—hematologic cancer	3.62e-05	0.000191	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—hematologic cancer	3.61e-05	0.00019	CcSEcCtD
Dapagliflozin—Constipation—Prednisone—hematologic cancer	3.6e-05	0.000189	CcSEcCtD
Dapagliflozin—Dizziness—Triamcinolone—hematologic cancer	3.52e-05	0.000185	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—hematologic cancer	3.51e-05	0.000185	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—hematologic cancer	3.49e-05	0.000184	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—hematologic cancer	3.48e-05	0.000184	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—hematologic cancer	3.48e-05	0.000183	CcSEcCtD
Dapagliflozin—Nausea—Prednisolone—hematologic cancer	3.44e-05	0.000181	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—hematologic cancer	3.41e-05	0.00018	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.41e-05	0.000179	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—hematologic cancer	3.4e-05	0.000179	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—hematologic cancer	3.39e-05	0.000179	CcSEcCtD
Dapagliflozin—Rash—Triamcinolone—hematologic cancer	3.36e-05	0.000177	CcSEcCtD
Dapagliflozin—Dermatitis—Triamcinolone—hematologic cancer	3.35e-05	0.000177	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—hematologic cancer	3.34e-05	0.000176	CcSEcCtD
Dapagliflozin—Headache—Triamcinolone—hematologic cancer	3.33e-05	0.000176	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—hematologic cancer	3.32e-05	0.000175	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—hematologic cancer	3.29e-05	0.000173	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—hematologic cancer	3.29e-05	0.000173	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—hematologic cancer	3.28e-05	0.000173	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—hematologic cancer	3.27e-05	0.000172	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—hematologic cancer	3.22e-05	0.00017	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—hematologic cancer	3.19e-05	0.000168	CcSEcCtD
Dapagliflozin—Dizziness—Dexamethasone—hematologic cancer	3.19e-05	0.000168	CcSEcCtD
Dapagliflozin—Dizziness—Betamethasone—hematologic cancer	3.19e-05	0.000168	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—hematologic cancer	3.18e-05	0.000167	CcSEcCtD
Dapagliflozin—Nausea—Triamcinolone—hematologic cancer	3.16e-05	0.000166	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.15e-05	0.000166	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—hematologic cancer	3.14e-05	0.000165	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisone—hematologic cancer	3.1e-05	0.000163	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—hematologic cancer	3.07e-05	0.000162	CcSEcCtD
Dapagliflozin—Rash—Dexamethasone—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Dapagliflozin—Rash—Betamethasone—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Dapagliflozin—Dermatitis—Dexamethasone—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Dapagliflozin—Dermatitis—Betamethasone—hematologic cancer	3.04e-05	0.00016	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.03e-05	0.00016	CcSEcCtD
Dapagliflozin—Headache—Dexamethasone—hematologic cancer	3.02e-05	0.000159	CcSEcCtD
Dapagliflozin—Headache—Betamethasone—hematologic cancer	3.02e-05	0.000159	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—hematologic cancer	3.02e-05	0.000159	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—hematologic cancer	2.96e-05	0.000156	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—hematologic cancer	2.94e-05	0.000155	CcSEcCtD
Dapagliflozin—Nausea—Betamethasone—hematologic cancer	2.87e-05	0.000151	CcSEcCtD
Dapagliflozin—Nausea—Dexamethasone—hematologic cancer	2.87e-05	0.000151	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—hematologic cancer	2.84e-05	0.00015	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.84e-05	0.00015	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—hematologic cancer	2.81e-05	0.000148	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—hematologic cancer	2.79e-05	0.000147	CcSEcCtD
Dapagliflozin—Dizziness—Prednisone—hematologic cancer	2.78e-05	0.000146	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—hematologic cancer	2.78e-05	0.000146	CcSEcCtD
Dapagliflozin—Rash—Prednisone—hematologic cancer	2.65e-05	0.00014	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—hematologic cancer	2.65e-05	0.00014	CcSEcCtD
Dapagliflozin—Headache—Prednisone—hematologic cancer	2.63e-05	0.000139	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.63e-05	0.000138	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—hematologic cancer	2.61e-05	0.000138	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—hematologic cancer	2.6e-05	0.000137	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—hematologic cancer	2.6e-05	0.000137	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—hematologic cancer	2.59e-05	0.000136	CcSEcCtD
Dapagliflozin—Nausea—Prednisone—hematologic cancer	2.5e-05	0.000132	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—hematologic cancer	2.42e-05	0.000128	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—hematologic cancer	2.42e-05	0.000127	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—hematologic cancer	2.41e-05	0.000127	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—hematologic cancer	2.32e-05	0.000122	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—hematologic cancer	2.24e-05	0.000118	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—hematologic cancer	2.22e-05	0.000117	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—hematologic cancer	2.21e-05	0.000117	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—hematologic cancer	2.2e-05	0.000116	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—hematologic cancer	2.17e-05	0.000115	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—hematologic cancer	2.09e-05	0.00011	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—hematologic cancer	2.07e-05	0.000109	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—hematologic cancer	2.07e-05	0.000109	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—hematologic cancer	2.06e-05	0.000109	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—hematologic cancer	2.01e-05	0.000106	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—hematologic cancer	1.95e-05	0.000103	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—hematologic cancer	1.92e-05	0.000101	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—hematologic cancer	1.92e-05	0.000101	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—hematologic cancer	1.91e-05	0.0001	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—hematologic cancer	1.81e-05	9.52e-05	CcSEcCtD
Dapagliflozin—CYP2D6—Metabolism—SLC22A1—hematologic cancer	4.41e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ACP5—hematologic cancer	4.39e-06	3.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA9—hematologic cancer	4.39e-06	3.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.38e-06	3.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ABCB1—hematologic cancer	4.37e-06	3.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC22A1—hematologic cancer	4.37e-06	3.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CRABP1—hematologic cancer	4.37e-06	3.8e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ALB—hematologic cancer	4.37e-06	3.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOR2—hematologic cancer	4.33e-06	3.77e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALOX5—hematologic cancer	4.3e-06	3.73e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.29e-06	3.73e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ADCY7—hematologic cancer	4.29e-06	3.72e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NCOA3—hematologic cancer	4.29e-06	3.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALOX5—hematologic cancer	4.26e-06	3.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NUP214—hematologic cancer	4.26e-06	3.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTM1—hematologic cancer	4.24e-06	3.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NCOR1—hematologic cancer	4.24e-06	3.69e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—hematologic cancer	4.22e-06	3.66e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3R1—hematologic cancer	4.18e-06	3.63e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTR—hematologic cancer	4.17e-06	3.62e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ABCG2—hematologic cancer	4.17e-06	3.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NUP98—hematologic cancer	4.16e-06	3.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—IDH1—hematologic cancer	4.13e-06	3.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NQO1—hematologic cancer	4.13e-06	3.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CD44—hematologic cancer	4.13e-06	3.59e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NUP98—hematologic cancer	4.12e-06	3.58e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO2—hematologic cancer	4.09e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CG—hematologic cancer	4.09e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTO1—hematologic cancer	4.08e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCC3—hematologic cancer	4.08e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TXN—hematologic cancer	4.08e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.04e-06	3.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADCY7—hematologic cancer	4.04e-06	3.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOA3—hematologic cancer	4.04e-06	3.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NUP214—hematologic cancer	4.01e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADCY7—hematologic cancer	4e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOA3—hematologic cancer	4e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SPHK1—hematologic cancer	4e-06	3.47e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FHL2—hematologic cancer	3.99e-06	3.46e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NUP214—hematologic cancer	3.98e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTT1—hematologic cancer	3.97e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.93e-06	3.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCG2—hematologic cancer	3.93e-06	3.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTR—hematologic cancer	3.93e-06	3.41e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AGRN—hematologic cancer	3.91e-06	3.4e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYCS—hematologic cancer	3.9e-06	3.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCG2—hematologic cancer	3.89e-06	3.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTR—hematologic cancer	3.89e-06	3.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HSP90AA1—hematologic cancer	3.88e-06	3.37e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SDC1—hematologic cancer	3.88e-06	3.37e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CB—hematologic cancer	3.86e-06	3.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO2—hematologic cancer	3.85e-06	3.35e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	3.85e-06	3.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—UGT1A1—hematologic cancer	3.84e-06	3.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO2—hematologic cancer	3.82e-06	3.32e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CREBBP—hematologic cancer	3.79e-06	3.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MTHFR—hematologic cancer	3.75e-06	3.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.74e-06	3.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC22A1—hematologic cancer	3.73e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CRABP1—hematologic cancer	3.73e-06	3.24e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.71e-06	3.23e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—IDH2—hematologic cancer	3.71e-06	3.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMMR—hematologic cancer	3.71e-06	3.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.7e-06	3.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SDC1—hematologic cancer	3.65e-06	3.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.65e-06	3.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALOX5—hematologic cancer	3.64e-06	3.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SDC1—hematologic cancer	3.62e-06	3.15e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CD—hematologic cancer	3.59e-06	3.12e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALB—hematologic cancer	3.55e-06	3.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NUP98—hematologic cancer	3.52e-06	3.06e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.49e-06	3.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.48e-06	3.03e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	3.48e-06	3.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.46e-06	3.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—hematologic cancer	3.44e-06	2.99e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOA3—hematologic cancer	3.42e-06	2.97e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADCY7—hematologic cancer	3.42e-06	2.97e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.41e-06	2.97e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NUP214—hematologic cancer	3.4e-06	2.95e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3R1—hematologic cancer	3.39e-06	2.95e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA9—hematologic cancer	3.39e-06	2.95e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ACP5—hematologic cancer	3.39e-06	2.95e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.36e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.35e-06	2.91e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—hematologic cancer	3.33e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.33e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTR—hematologic cancer	3.33e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCG2—hematologic cancer	3.33e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NQO1—hematologic cancer	3.3e-06	2.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CD44—hematologic cancer	3.3e-06	2.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.27e-06	2.84e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO2—hematologic cancer	3.26e-06	2.84e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—hematologic cancer	3.26e-06	2.83e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—IDH1—hematologic cancer	3.19e-06	2.77e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—hematologic cancer	3.18e-06	2.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—hematologic cancer	3.17e-06	2.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NCOR1—hematologic cancer	3.16e-06	2.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—hematologic cancer	3.16e-06	2.75e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—hematologic cancer	3.15e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TXN—hematologic cancer	3.15e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.15e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.15e-06	2.74e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—hematologic cancer	3.13e-06	2.72e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYCS—hematologic cancer	3.12e-06	2.71e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.12e-06	2.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NQO1—hematologic cancer	3.11e-06	2.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CD44—hematologic cancer	3.11e-06	2.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.1e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SDC1—hematologic cancer	3.09e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.08e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CD44—hematologic cancer	3.08e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NQO1—hematologic cancer	3.08e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.01e-06	2.62e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.96e-06	2.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.96e-06	2.57e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYCS—hematologic cancer	2.94e-06	2.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CREBBP—hematologic cancer	2.92e-06	2.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.92e-06	2.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.92e-06	2.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYCS—hematologic cancer	2.91e-06	2.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	2.89e-06	2.52e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.88e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.88e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.81e-06	2.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—hematologic cancer	2.8e-06	2.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.79e-06	2.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—hematologic cancer	2.77e-06	2.41e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—hematologic cancer	2.75e-06	2.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—hematologic cancer	2.74e-06	2.38e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NUP98—hematologic cancer	2.72e-06	2.36e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—hematologic cancer	2.71e-06	2.35e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.64e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.64e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NQO1—hematologic cancer	2.63e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CD44—hematologic cancer	2.63e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NUP214—hematologic cancer	2.62e-06	2.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3R1—hematologic cancer	2.62e-06	2.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.61e-06	2.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.59e-06	2.25e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—hematologic cancer	2.58e-06	2.24e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.58e-06	2.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTR—hematologic cancer	2.57e-06	2.23e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.57e-06	2.23e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.57e-06	2.23e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—hematologic cancer	2.53e-06	2.19e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NCOR1—hematologic cancer	2.53e-06	2.19e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO2—hematologic cancer	2.52e-06	2.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYCS—hematologic cancer	2.49e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.48e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.47e-06	2.15e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.46e-06	2.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.45e-06	2.13e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.44e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.43e-06	2.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—hematologic cancer	2.42e-06	2.1e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SDC1—hematologic cancer	2.39e-06	2.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.38e-06	2.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.38e-06	2.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.36e-06	2.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.36e-06	2.05e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—hematologic cancer	2.35e-06	2.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—hematologic cancer	2.35e-06	2.04e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—hematologic cancer	2.23e-06	1.94e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.23e-06	1.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.19e-06	1.91e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CREBBP—hematologic cancer	2.18e-06	1.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.12e-06	1.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.1e-06	1.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—hematologic cancer	2.09e-06	1.81e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.09e-06	1.81e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.08e-06	1.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—hematologic cancer	2.06e-06	1.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—hematologic cancer	2.04e-06	1.77e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CD44—hematologic cancer	2.03e-06	1.76e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NQO1—hematologic cancer	2.03e-06	1.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.02e-06	1.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.02e-06	1.75e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—hematologic cancer	1.99e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.95e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYCS—hematologic cancer	1.92e-06	1.67e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—hematologic cancer	1.92e-06	1.67e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—hematologic cancer	1.91e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.91e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.88e-06	1.63e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.84e-06	1.6e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.8e-06	1.56e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.78e-06	1.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.77e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.75e-06	1.52e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CREBBP—hematologic cancer	1.74e-06	1.51e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.69e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.65e-06	1.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.64e-06	1.42e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—hematologic cancer	1.63e-06	1.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.62e-06	1.41e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.6e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.57e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—hematologic cancer	1.56e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.56e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.56e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.56e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—hematologic cancer	1.55e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.55e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.54e-06	1.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—hematologic cancer	1.53e-06	1.33e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—hematologic cancer	1.52e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.5e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—hematologic cancer	1.48e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—hematologic cancer	1.47e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.47e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.45e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.44e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.39e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.38e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.35e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.34e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.32e-06	1.14e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—hematologic cancer	1.3e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.24e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—hematologic cancer	1.24e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—hematologic cancer	1.2e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—hematologic cancer	1.18e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—hematologic cancer	1.17e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—hematologic cancer	1.16e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.16e-06	1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.15e-06	9.97e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—hematologic cancer	1.12e-06	9.7e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—hematologic cancer	1.11e-06	9.61e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—hematologic cancer	1.1e-06	9.53e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.07e-06	9.31e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.02e-06	8.83e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—hematologic cancer	1e-06	8.71e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—hematologic cancer	9.91e-07	8.61e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	9.59e-07	8.34e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—hematologic cancer	9.46e-07	8.22e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—hematologic cancer	8.96e-07	7.79e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.85e-07	7.69e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—hematologic cancer	8.76e-07	7.61e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—hematologic cancer	8.26e-07	7.17e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—hematologic cancer	8.18e-07	7.11e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—hematologic cancer	7.65e-07	6.65e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—hematologic cancer	7.3e-07	6.34e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—hematologic cancer	7.16e-07	6.22e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.99e-07	6.08e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—hematologic cancer	6.74e-07	5.86e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—hematologic cancer	6.69e-07	5.81e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—hematologic cancer	5.71e-07	4.96e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.4e-07	4.69e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—hematologic cancer	4.41e-07	3.83e-06	CbGpPWpGaD
